American Century Companies Inc. Acquires 732 Shares of AveXis (AVXS)

American Century Companies Inc. grew its holdings in shares of AveXis (NASDAQ:AVXS) by 4.1% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 18,534 shares of the company’s stock after purchasing an additional 732 shares during the period. American Century Companies Inc. owned approximately 0.05% of AveXis worth $2,290,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the company. Eagle Asset Management Inc. lifted its holdings in shares of AveXis by 123.4% during the fourth quarter. Eagle Asset Management Inc. now owns 354,154 shares of the company’s stock valued at $39,274,000 after purchasing an additional 195,626 shares during the last quarter. Deutsche Bank AG lifted its holdings in shares of AveXis by 42.7% during the fourth quarter. Deutsche Bank AG now owns 303,901 shares of the company’s stock valued at $33,630,000 after purchasing an additional 90,934 shares during the last quarter. Geode Capital Management LLC raised its holdings in AveXis by 1.5% in the 4th quarter. Geode Capital Management LLC now owns 220,779 shares of the company’s stock worth $24,433,000 after acquiring an additional 3,204 shares during the last quarter. TimesSquare Capital Management LLC raised its holdings in AveXis by 6.9% in the 4th quarter. TimesSquare Capital Management LLC now owns 219,890 shares of the company’s stock worth $24,335,000 after acquiring an additional 14,250 shares during the last quarter. Finally, Carillon Tower Advisers Inc. purchased a new position in AveXis in the 4th quarter worth approximately $24,033,000. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Get AveXis alerts:

In other news, VP James J. Litalien sold 5,000 shares of the business’s stock in a transaction on Monday, April 2nd. The shares were sold at an average price of $119.44, for a total transaction of $597,200.00. Following the completion of the sale, the vice president now owns 8,800 shares of the company’s stock, valued at approximately $1,051,072. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Sukumar Nagendran sold 1,780 shares of the business’s stock in a transaction on Thursday, March 1st. The shares were sold at an average price of $126.19, for a total transaction of $224,618.20. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 46,780 shares of company stock valued at $5,801,268. Company insiders own 18.60% of the company’s stock.

Shares of AVXS opened at $217.83 on Monday. The firm has a market cap of $8.02 billion, a price-to-earnings ratio of -29.92 and a beta of 1.55. AveXis has a 1-year low of $65.54 and a 1-year high of $217.94.

AveXis (NASDAQ:AVXS) last announced its earnings results on Wednesday, May 9th. The company reported ($6.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.32) by ($2.88). equities research analysts predict that AveXis will post -9.69 earnings per share for the current year.

A number of equities analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of AveXis from a “strong sell” rating to a “hold” rating in a report on Monday, May 7th. Jefferies Group lowered shares of AveXis from a “buy” rating to a “hold” rating in a report on Wednesday, April 18th. Chardan Capital lowered shares of AveXis from a “buy” rating to a “neutral” rating in a report on Friday, April 13th. Barclays lowered shares of AveXis from an “overweight” rating to an “equal weight” rating and set a $152.00 price objective for the company. in a report on Thursday, April 12th. Finally, UBS lowered shares of AveXis from a “buy” rating to a “neutral” rating in a report on Thursday, April 12th. One equities research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and six have assigned a buy rating to the company’s stock. AveXis currently has a consensus rating of “Hold” and an average price target of $123.90.

AveXis Company Profile

AveXis, Inc, a clinical-stage gene therapy company, engages in developing and commercializing treatments for patients suffering from rare and life-threatening neurological genetic diseases. Its initial product candidate is AVXS-101, a gene therapy product candidate that has completed Phase I clinical trial for the treatment of spinal muscular atrophy Type 1.